MiMedx击败了2025年第四季度的财报，但由于医疗保险新实施的皮肤替代品价格上限，2026年第一季度将面临下滑。 MiMedx beat Q4 2025 earnings but faces Q1 2026 slump due to Medicare’s new skin substitute pricing cap.

米梅德克斯报告,2025年Q4成果强劲,收入为1.181亿美元,每股收入为14美元,超过预期,其驱动因素是伤口护理和外科部门增长25。 MiMedx reported strong Q4 2025 results with revenue of $118.1 million and earnings of $0.14 per share, surpassing expectations, driven by 25%+ growth in both wound care and surgical segments. 该公司全年收入增长27%,自由现金流量2 500万美元,净现金头寸为1.48亿美元。 The company posted a 27% year-over-year revenue increase, $25 million in free cash flow, and a net cash position of $148 million. 尽管由于Medicare公司为皮肤代用品规定了新的127平方厘米价格上限(造成索赔缓慢、供应商关闭和价格倾销),2026年问题1,收入显著下降,但管理层预计到2027年稳定下来并恢复两位数的增长。 Despite a significant revenue drop in Q1 2026 due to Medicare’s new $127 per square centimeter price cap for skin substitutes—causing slower claims, provider closures, and price dumping—management expects stabilization and a return to double-digit growth by 2027. 该公司批准了1亿美元的股份回购,推出了新的外科产品,并进行了先进的临床试验。 The company approved a $100 million share repurchase, launched new surgical products, and advanced clinical trials. 2026年全年收入指导为3.4亿美元-360亿美元,低于共识,反映了持续偿还方面的挑战。 Full-year 2026 revenue guidance is $340M–$360M, below consensus, reflecting ongoing reimbursement challenges.